Common Contracts
4 similar Sales Agreement contracts by Provention Bio, Inc., Innovate Biopharmaceuticals, Inc., Kura Oncology, Inc.
KURA ONCOLOGY, INC. COMMON STOCK SALES AGREEMENTSales Agreement • November 2nd, 2023 • Kura Oncology, Inc. • Pharmaceutical preparations • New York
Kura Oncology, Inc., a Delaware corporation (the “Company”), Leerink Partners LLC (“Leerink Partners”), as lead sales agent, and Cantor Fitzgerald & Co. (“Cantor”, and together with Leerink Partners, the “Agents”), as sales agent, confirm their agreement (this “Agreement”) as follows:
Provention Bio, Inc. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENTSales Agreement • February 26th, 2021 • Provention Bio, Inc. • Pharmaceutical preparations • New York
Provention Bio, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Leerink LLC and Cantor Fitzgerald & Co. (each individually, an “Agent” and collectively, the “Agents”), as follows:
Provention Bio, Inc. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENTSales Agreement • August 2nd, 2019 • Provention Bio, Inc. • Pharmaceutical preparations • New York
Provention Bio, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Leerink LLC and Cantor Fitzgerald & Co. (each individually, an “Agent” and collectively, the “Agents”), as follows:
INNOVATE BIOPHARMACEUTICALS, INC. COMMON STOCK SALES AGREEMENTSales Agreement • October 29th, 2018 • Innovate Biopharmaceuticals, Inc. • Pharmaceutical preparations • New York
Innovate Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), confirms its agreement (this "Agreement") with H.C. Wainwright & Co., LLC ("HCW") and Ladenburg Thalmann & Co. Inc. ("Ladenburg", each of HCW and Ladenburg individually an "Agent" and collectively, the "Agents"), as follows:
